Evidence map›Paper›PMID 39704178›Full record

ArticleHaematologica2025

Potassium/sodium cation carriers robustly upregulate CD20 antigen by targeting MYC, and synergize with anti- CD20 immunotherapies to eliminate malignant B cells.

Anna Torun, Aleksandra Zdanowicz, Nina Miazek-Zapala, Piotr Zapala, Bhaskar Pradhan, Marta Jedrzejczyk, Andrzej Ciechanowicz, Zofia Pilch, Marcin Skorzynski, Mikołaj Słabicki and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Anna TorunMedical University of Warsaw, Warsaw.
Aleksandra ZdanowiczMedical University of Warsaw, Warsaw, Poland; Doctoral School, Medical University of Warsaw, Warsaw.
Nina Miazek-ZapalaMedical University of Warsaw, Warsaw.
Piotr ZapalaMedical University of Warsaw, Warsaw.
Bhaskar PradhanMedical University of Warsaw, Warsaw, Poland; Doctoral School, Medical University of Warsaw, Warsaw.
Marta JedrzejczykAdam Mickiewicz University, Poznan.
Andrzej CiechanowiczMedical University of Warsaw, Warsaw.
Zofia PilchMedical University of Warsaw, Warsaw.
Marcin SkorzynskiMedical University of Warsaw, Warsaw.
Mikołaj SłabickiBroad Institute of MIT and Harvard, Cambridge, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA.
Grzegorz RymkiewiczMaria Sklodowska-Curie National Research Institute of Oncology, Warsaw.
Joanna BarankiewiczInstitute of Hematology and Transfusion Medicine, Warsaw.
Claudio MartinesMolecular Hematology Unit, International Centre for Genetic Engineering and Biotechnology, Trieste.
Luca LaurentiHematology Unit, Fundazione Policlinico Universitario A Gemelli IRCCS, Rome.
Marta StrugaMedical University of Warsaw, Warsaw.
Magdalena WiniarskaMedical University of Warsaw, Warsaw.
Jakub GolabMedical University of Warsaw, Warsaw.
Magdalena KuciaMedical University of Warsaw, Warsaw.
Mariusz Z RatajczakMedical University of Warsaw, Warsaw.
Adam HuczynskiAdam Mickiewicz University, Poznan.
Dinis P CaladoThe Francis Crick Institute, London, United Kingdom.
Dimitar G EfremovMolecular Hematology Unit, International Centre for Genetic Engineering and Biotechnology, Trieste.
Abdessamad ZerrouqiMedical University of Warsaw, Warsaw, Poland; Senior authors.
Beata PyrzynskaMedical University of Warsaw, Warsaw, Poland; Senior authors. beata.pyrzynska@wum.edu.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our investigation uncovers that nanomolar concentrations of salinomycin, monensin, nigericin, and narasin (a group of potassium/ sodium cation carriers) robustly enhance surface expression of CD20 antigen in B-cell-derived tumor cells, including primary malignant cells of chronic lymphocytic leukemia and diffuse large B-cell lymphoma. Experiments in vitro, ex vivo, and animal model reveal a novel approach of combining salinomycin or monensin with therapeutic anti-CD20 monoclonal antibodies or anti-CD20 chimeric antigen receptor T cells, significantly improving non-Hodgkin lymphoma therapy. The results of RNA sequencing, genetic editing, and chemical inhibition delineate the molecular mechanism of CD20 upregulation, at least partially, to the downregulation of MYC, the transcriptional repressor of the MS4A1 gene encoding CD20. Our findings propose the cation carriers as compounds targeting MYC oncogene, which can be combined with anti-CD20 antibodies or adoptive cellular therapies to treat non-Hodgkin lymphoma and mitigate resistance, which frequently depends on the CD20 antigen loss, offering new solutions to improve patient outcomes.

Indexed as

Antigens, CD20B-LymphocytesImmunotherapyProto-Oncogene Proteins c-mycAnimalsCell Line, TumorHumansLeukemia, Lymphocytic, Chronic, B-CellMiceUp-RegulationAntigens, CD20MYC protein, humanProto-Oncogene Proteins c-myc

Identifiers

PMID39704178
PMCPMC12208165

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.